Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Aldeyra Therapeutics, Inc. ALDX
$10.14
-$0.21 (-2.03%)
На 18:00, 12 мая 2023
+156.41%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
602458274.00000000
-
week52high
10.89
-
week52low
2.36
-
Revenue
0
-
P/E TTM
-10
-
Beta
1.12145300
-
EPS
-1.13000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 авг 2023 г. в 12:30
Описание компании
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Citigroup | Buy | Buy | 09 июн 2022 г. |
| SVB Leerink | Outperform | Outperform | 21 дек 2021 г. |
| Citigroup | Buy | Buy | 21 дек 2021 г. |
| SVB Leerink | Outperform | 12 мар 2021 г. | |
| HC Wainwright & Co. | Buy | 08 февр 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | A | 11350085 | 15000 | 10 авг 2022 г. |
| PERCEPTIVE ADVISORS LLC | A | 11335085 | 100000 | 09 авг 2022 г. |
| PERCEPTIVE ADVISORS LLC | A | 11235085 | 97000 | 08 авг 2022 г. |
| PERCEPTIVE ADVISORS LLC | A | 11138085 | 141000 | 05 авг 2022 г. |
| PERCEPTIVE ADVISORS LLC | A | 10997085 | 95100 | 04 авг 2022 г. |
| PERCEPTIVE ADVISORS LLC | A | 10901985 | 100000 | 03 авг 2022 г. |
| PERCEPTIVE ADVISORS LLC | A | 10801985 | 412406 | 02 авг 2022 г. |
| PERCEPTIVE ADVISORS LLC | A | 10389579 | 144185 | 01 авг 2022 г. |
| PERCEPTIVE ADVISORS LLC | A | 10245394 | 222123 | 29 июл 2022 г. |
| PERCEPTIVE ADVISORS LLC | A | 10023271 | 119392 | 28 июл 2022 г. |
Новостная лента
Buy Aldeyra Therapeutics For Consecutive Runups
Seeking Alpha
06 мая 2023 г. в 01:23
They headlined 3 top-line results coming in Q2 2023. An all-important PDUFA Date is on tap in June.
Aldeyra Therapeutics, Inc. (ALDX) Q4 2022 Earnings Call Transcript
Seeking Alpha
09 мар 2023 г. в 10:45
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX ) Q4 2022 Earnings Conference Call March 9, 2023 8:00 AM ET Company Participants Bruce Greenberg - Interim Chief Financial Officer Todd Brady - President and Chief Executive Officer Conference Call Participants Marc Goodman - SVB Securities Yigal Nochomovitz - Citigroup Justin Kim - Oppenheimer & Co. Catherine Novack - Jones Research Yale Jen - Laidlaw & Company Operator Ladies and gentlemen, thank you for standing by, and welcome to the Aldeyra Therapeutics Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Aldeyra Therapeutics: NDA Submission For Large Multi-Billion Dollar Market
Seeking Alpha
11 дек 2022 г. в 07:17
New Drug Application of Reproxalap for the treatment of patients with dry eye disease submitted on November 29, 2022; Potential FDA approval possible in late 2023. Results from the phase 3 INVIGORATE-2 study using reproxalap for the treatment of patients with allergic conjunctivitis are expected in 2023.
Aldeyra Therapeutics, Inc. (ALDX) Q3 2022 Earnings Call Transcript
Seeking Alpha
10 ноя 2022 г. в 13:40
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX ) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Bruce Greenberg - Interim Chief Financial Officer Todd Brady - President and Chief Executive Officer Conference Call Participants Marc Goodman - SVB Securities Justin Kim - Oppenheimer Yale Jen - Laidlaw & Co. Catherine Novack - Jones Research Operator Ladies and gentlemen, thank you for standing by and welcome to the Aldeyra Therapeutics Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
Business Wire
05 окт 2022 г. в 16:05
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, October 6, 2022, at 8:00 a.m. (ET) to report top-line results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 (methotrexate injection, United States Pharmacopeia) for intravitreal administration in patients with proliferative vitreoretinopathy (PVR), a rare, sight-threatening ocular disease with no approved therapy. The dial-in numbers